Ferumoxytol (Feraheme)
For more on this Drug Safety Labeling Change, click here.
For full prescribing information, click here.
Updated Boxed Warning
WARNING: RISK FOR SERIOUS HYPERSENSITIVITY/ANAPHYLAXIS REACTIONS
Fatal and serious hypersensitivity reactions, including anaphylaxis, have occurred in patients receiving Feraheme. Initial symptoms may include hypotension, syncope, unresponsiveness, and cardiac/cardiorespiratory arrest.
Only administer Feraheme as an intravenous infusion over at least 15 minutes and only when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions.
Public Information from the FDA and Medscape. Information provided by FDA and/or its employees on this website is for educational purposes only, and does not constitute medical advice. Any statement or advice given by an FDA employee on this website does not represent the formal position of FDA. FDA and/or any FDA employee will not be liable for injury or other damages resulting to any individuals who view FDA-related materials on this website.
Cite this: Shannon Thor. Drug Safety Warnings and Updates: January-March 2018 - Medscape - May 23, 2018.
